Photocure (PHO) Stock Overview
Engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PHO Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Photocure ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 58.20 |
| 52 Week High | NOK 71.80 |
| 52 Week Low | NOK 47.20 |
| Beta | 0.50 |
| 1 Month Change | -2.18% |
| 3 Month Change | -7.91% |
| 1 Year Change | 14.12% |
| 3 Year Change | -42.03% |
| 5 Year Change | -30.05% |
| Change since IPO | -69.04% |
Recent News & Updates
Recent updates
Photocure ASA (OB:PHO) Stock Rockets 29% But Many Are Still Ignoring The Company
Jul 18
Photocure ASA (OB:PHO) Could Be Riskier Than It Looks
Apr 05
Advancements In BLC Technology And Hexvix Launch Will Revolutionize Bladder Cancer Diagnosis
Strategic initiatives in the U.S. and Europe, such as Blue Light Cystoscopy expansion and partnerships, are expected to drive significant revenue and market growth.Photocure ASA's (OB:PHO) Shares Leap 29% Yet They're Still Not Telling The Full Story
Dec 21We Think Photocure's (OB:PHO) Robust Earnings Are Conservative
Aug 14Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable
Jun 01Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors
Dec 18Potential Upside For Photocure ASA (OB:PHO) Not Without Risk
Sep 01Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook
Mar 01Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report
Aug 14We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt
Aug 12Shareholder Returns
| PHO | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 14.3% | -2.6% | -1.6% |
| 1Y | 14.1% | -14.1% | 5.3% |
Return vs Industry: PHO exceeded the Norwegian Pharmaceuticals industry which returned -12.5% over the past year.
Return vs Market: PHO exceeded the Norwegian Market which returned 5.1% over the past year.
Price Volatility
| PHO volatility | |
|---|---|
| PHO Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: PHO has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: PHO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 100 | Dan Schneider | www.photocure.com |
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
Photocure ASA Fundamentals Summary
| PHO fundamental statistics | |
|---|---|
| Market cap | NOK 1.55b |
| Earnings (TTM) | NOK 2.12m |
| Revenue (TTM) | NOK 537.59m |
Is PHO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHO income statement (TTM) | |
|---|---|
| Revenue | NOK 537.59m |
| Cost of Revenue | NOK 38.55m |
| Gross Profit | NOK 499.04m |
| Other Expenses | NOK 496.92m |
| Earnings | NOK 2.12m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.08 |
| Gross Margin | 92.83% |
| Net Profit Margin | 0.39% |
| Debt/Equity Ratio | 0% |
How did PHO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 06:26 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Photocure ASA is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Geir Holom | DNB Carnegie |
| Maxim Jacobs | Edison Investment Research |